BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 21456632)

  • 1. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
    Yubero-Lahoz S; Pardo R; Farré M; O'Mahony B; Torrens M; Mustata C; Pérez-Mañá C; Carbó ML; de la Torre R
    Clin Pharmacokinet; 2011 May; 50(5):319-29. PubMed ID: 21456632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.
    Segura M; Farré M; Pichini S; Peiró AM; Roset PN; Ramírez A; Ortuño J; Pacifici R; Zuccaro P; Segura J; de la Torre R
    Clin Pharmacokinet; 2005; 44(6):649-60. PubMed ID: 15910012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.
    O'Mathúna B; Farré M; Rostami-Hodjegan A; Yang J; Cuyàs E; Torrens M; Pardo R; Abanades S; Maluf S; Tucker GT; de la Torre R
    J Clin Psychopharmacol; 2008 Oct; 28(5):523-9. PubMed ID: 18794647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the Ecstasy influence on tramadol and its main metabolite plasma concentration in rats.
    Jamali B; Sheikholeslami B; Hosseinzadeh Ardakani Y; Lavasani H; Rouini MR
    Drug Metab Pers Ther; 2017 Sep; 32(3):137-145. PubMed ID: 28917081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).
    Van LM; Heydari A; Yang J; Hargreaves J; Rowland-Yeo K; Lennard MS; Tucker GT; Rostami-Hodjegan A
    J Psychopharmacol; 2006 Nov; 20(6):834-41. PubMed ID: 16478752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in CYP1A2 activity in humans after 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) administration using caffeine as a probe drug.
    Yubero-Lahoz S; Pardo R; Farre M; Mathuna BÓ; Torrens M; Mustata C; Perez-Mañá C; Langohr K; Carbó ML; de la Torre R
    Drug Metab Pharmacokinet; 2012; 27(6):605-13. PubMed ID: 22673010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
    Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
    Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro.
    Ramamoorthy Y; Yu AM; Suh N; Haining RL; Tyndale RF; Sellers EM
    Biochem Pharmacol; 2002 Jun; 63(12):2111-9. PubMed ID: 12110370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.
    Steuer AE; Schmidhauser C; Tingelhoff EH; Schmid Y; Rickli A; Kraemer T; Liechti ME
    PLoS One; 2016; 11(3):e0150955. PubMed ID: 26967321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice.
    Jurica J; Bartecek R; Zourkova A; Pindurova E; Sulcova A; Kasparek T; Zendulka O
    J Clin Pharm Ther; 2012 Aug; 37(4):486-90. PubMed ID: 22548589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
    Schadel M; Wu D; Otton SV; Kalow W; Sellers EM
    J Clin Psychopharmacol; 1995 Aug; 15(4):263-9. PubMed ID: 7593709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates.
    Labbé L; Sirois C; Pilote S; Arseneault M; Robitaille NM; Turgeon J; Hamelin BA
    Pharmacogenetics; 2000 Jul; 10(5):425-38. PubMed ID: 10898112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
    Capon DA; Bochner F; Kerry N; Mikus G; Danz C; Somogyi AA
    Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Curcuma longa on CYP2D6- and CYP3A4-mediated metabolism of dextromethorphan in human liver microsomes and healthy human subjects.
    Al-Jenoobi FI; Al-Thukair AA; Alam MA; Abbas FA; Al-Mohizea AM; Alkharfy KM; Al-Suwayeh SA
    Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):61-6. PubMed ID: 24510399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.
    McCune JS; Lindley C; Decker JL; Williamson KM; Meadowcroft AM; Graff D; Sawyer WT; Blough DK; Pieper JA
    J Clin Pharmacol; 2001 Jul; 41(7):723-31. PubMed ID: 11452704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
    Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT).
    Pardo-Lozano R; Farré M; Yubero-Lahoz S; O'Mathúna B; Torrens M; Mustata C; Pérez-Mañá C; Langohr K; Cuyàs E; Carbó Ml; de la Torre R
    PLoS One; 2012; 7(10):e47599. PubMed ID: 23112822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic mechanism of time-dependent inhibition of CYP2D6 by 3,4-methylenedioxymethamphetamine (MDMA): Functional heterogeneity of the enzyme and the reversibility of its inactivation.
    Rodgers JT; Davydova NY; Paragas EM; Jones JP; Davydov DR
    Biochem Pharmacol; 2018 Oct; 156():86-98. PubMed ID: 30114388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
    Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
    Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics.
    Farré M; Abanades S; Roset PN; Peiró AM; Torrens M; O'Mathúna B; Segura M; de la Torre R
    J Pharmacol Exp Ther; 2007 Dec; 323(3):954-62. PubMed ID: 17890444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.